Literature DB >> 9893017

Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours.

U Wulbrand1, M Wied, P Zöfel, B Göke, R Arnold, H Fehmann.   

Abstract

BACKGROUND: Human gastroenteropancreatic neuroendocrine tumours are functionally and biologically heterogeneous, but their exact growth factor receptor expression pattern, important for onco- and carcinogenesis, remains unknown.
METHODS: This study searched for the mRNA expression pattern of six tyrosine- and serine/threonine kinase receptors [hepatocyte growth factor (HGFR), fibroblast growth factor (FGFR), epidermal growth factor (EGFR), insulin-like growth factor (IGF)-1R, transforming growth factor (TGF)-betaR1, TGF-betaR2] together with the five somatostatin receptors in human gastroenteropancreatic neuroendocrine tumours (gastrinomas, insulinomas, tumours with carcinoid syndrome, functionally inactive neuroendocrine tumours) using reverse transcriptase-polymerase chain reaction (RT-PCR).
RESULTS: EGF receptor was expressed almost exclusively in gastrinomas. Among the four tumour subtypes, expression frequencies of the somatostatin receptors 1 and 5, HGF-, IGF-1-, TGF-betaR1, TGF-betaR2 and the EGF-receptor varied significantly.
CONCLUSIONS: In spite of the common cellular origin of these tumours, differences in growth factor receptor expression suggest the existence of different pathways during tumour subtype development.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9893017     DOI: 10.1046/j.1365-2362.1998.00397.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  27 in total

Review 1.  EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets.

Authors:  M Kidd; S Schimmack; B Lawrence; D Alaimo; I M Modlin
Journal:  Neuroendocrinology       Date:  2012-06-15       Impact factor: 4.914

Review 2.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 3.  Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Mark Kidd; Irvin Modlin; Kjell Öberg
Journal:  Nat Rev Clin Oncol       Date:  2016-06-07       Impact factor: 66.675

4.  Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor.

Authors:  Alessia Di Florio; Veronica Sancho; Paola Moreno; Gianfranco Delle Fave; Robert T Jensen
Journal:  Biochim Biophys Acta       Date:  2012-12-04

Review 5.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

Review 6.  Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.

Authors:  Rossana Berardi; Francesca Morgese; Mariangela Torniai; Agnese Savini; Stefano Partelli; Silvia Rinaldi; Miriam Caramanti; Consuelo Ferrini; Massimo Falconi; Stefano Cascinu
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

7.  Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.

Authors:  Patricia Grabowski; Isrid Sturm; Katharina Schelwies; Kerstin Maaser; Heinz-Johannes Buhr; Bernd Dörken; Martin Zeitz; Peter T Daniel; Hans Scherübl
Journal:  Int J Colorectal Dis       Date:  2005-06-14       Impact factor: 2.571

8.  Minute gastric carcinoid tumor with regional lymph node metastasis: a case report and review of literature.

Authors:  Shu-Duo Xie; Lin-Bo Wang; Xiang-Yang Song; Tao Pan
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

9.  Genetic polymorphisms of inflammatory response gene TNF-α and its influence on sporadic pancreatic neuroendocrine tumors predisposition risk.

Authors:  Dimitrios Karakaxas; Maria Gazouli; Ahmet Coker; Christos Agalianos; Ioannis S Papanikolaou; Pavlos Patapis; Theodoros Liakakos; Christos Dervenis
Journal:  Med Oncol       Date:  2014-09-12       Impact factor: 3.064

Review 10.  Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms.

Authors:  Namrata Vijayvergia; Arvind Dasari
Journal:  Curr Treat Options Oncol       Date:  2020-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.